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Summary The expression of p53 protein was examined in a series of 136 primary breast carcinomas, 106 of
which were analysed with a panel of four monoclonal antibodies (MAbs 1801, 240, D07 and DOI). p53
expression was detected with at least one antibody in 40 tumours (38%), whereas only 15 tumours (14%) were
positive with all four antibodies. Some variability in the immunostaining could be observed depending on the
antibody used. This was noticeable both for the number of positive cells within a section and for the intensity
of staining. We therefore selected a panel of 17 tumour sections (nine were highly positive, three with medium
to low staining and five with low to negative staining), which we analysed by polymerase chain reaction-
single-strand conformation polymorphism analysis (PCR-SSCP) for the presence of a p53 mutation at the
molecular level. Mutations were identified in 15 cases. Therefore the proportion of p53-stained cells does not
seem to be an exact representation of the number of cancer cells bearing a mutation within a tumour. A
statistically significant correlation was observed between p53 expression, regardless of the number of positive
antibodies, and grade III disease (P<0.0001), oestrogen (P<0.0001) or progesterone receptor negativity
(P = 0.0061), increased Ki 67 index (P = 0.0018), epidermal growth factor receptor (EGFR) positivity
(P = 0.0076) and aneuploidy (P = 0.037). No correlation was observed with tumour size or lymph node
involvement. In univariate analysis p53 expression was not correlated with disease-free survival, in contrast to
the classical prognostic parameters, which were statistically correlated. In this series p53 expression was not a
marker of early recurrence.
The identification of biological and molecular parameters
allowing discrimination between subsets of breast cancers is
an important challenge for improved management of the
disease. Currently, clinical parameters such as TNM staging,
metastatic involvement of axillary lymph nodes and histo-
logical grading remain the major prognostic factors (Fisher et
al., 1975; Contesso et al., 1987). However, biological para-
meters such as hormone receptor status and DNA ploidy
have also proven helpful (Clark et al., 1989; McGuire et al.,
1990). More recently, studies on alterations affecting onco-
genes and anti-oncogenes have suggested that these may also
become interesting prognostic indicators (Slamon et al., 1989;
Gullick et al., 1990).
Inactivation or abnormal expression of anti-oncogenes
appears to play an important role in the genesis and/or
progression of cancer. The wild-type p53 protein possesses
growth-suppressing potential and acts as a cell cycle check-
point, whereas its mutated counterpart either loses its anti-
oncogene characteristics or acquires oncogenic potential
(Lane & Benchimol, 1990; Kastan et al., 1992). These proper-
ties, added to the observation by Nigro et al. (1989) that p53
could be mutated in a substantial proportion of colon car-
cinomas, quickly made this gene the most studied topic in
human cancer. p53 turned out to be the most frequently
altered gene in human tumours, since all the cancer types
analysed to date have displayed p53 mutations, although at
varying frequencies (Hollstein et al., 1991). An interesting
characteristic of p53 mutations (reviewed in Caron de
Fromentel & Soussi, 1992) lies in the increased stability of
the mutated protein, whose half-life is increased by a factor
of 10-20 as compared with the wild-type protein (Lane &
Benchimol, 1990). This leads to the accumulation of mutated
p53 protein in the cell nucleus, which makes it detectable by
standard immunostaining procedures (Lane & Benchimol,
1990). This property has prompted a large number of studies
on p53 protein expression in various tumours, including
breast carcinomas (Catoretti et al., 1988; Bartek et al., l990a,
b).
It was quickly found out that p53 immunoreactivity could
bear some prognostic significance. Mutated or overexpressed
p53 was correlated with markers of poor prognosis such as
high histopathological grading, high levels of Ki 67 or EGF
receptor, absence of hormone receptors, as well as with a
shortened disease-free or overall survival (Catoretti et al.,
1988; Davidoff et al., 1991a; Horak et al., 1991; Iwaha et al.,
1991; Ostrowski et al., 1991; Barbareschi et al., 1992; Isola et
al., 1992; Poller et al., 1992; Thor et al., 1992; Allred et al.,
1993; Barnes et al., 1993; Silvestrini et al., 1993). However,
variations can be found from one study to another concern-
ing the frequencies of positively stained tumours, which vary
from 20 to 55%. Patterns of immunoreactivity also show
some variability, since staining could either be purely nuclear
or fully cytoplasmic (Horak et al., 1991). It has, furthermore,
been noticed that the frequency of p53 mutants detected by
immunostaining is often twice as high as by polymerase chain
reaction (PCR)-based methods such as single-strand confor-
mation polymorphism (SSCP), denaturation gradient gel elec-
trophoresis (DGGE) or chemical cleavage (Mazars et al.,
1992).
These elements led us to evaluate the detection of p53
accumulation in a series of breast tumours for which sections
could be made from both frozen and formalin-fixed/paraffin-
embedded tissues. In the present work, we analysed p53
immunostaining using four monoclonal antibodies on frozen
and/or fixed tissues, and calculated its prognostic
significance. In addition, we cross-correlated the presence of
a mutation at the molecular level by performing a PCR-
SSCP analysis on a selected set of positively stained sec-
tions.
Materials and methods
Patients and tumour samples
A series of 136 patients with breast carcinoma diagnosed
between January 1988 and December 1992 was analysed. The
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median follow-up of these patients was short, 10.7 months
(range 6 months to 4 years). Breast cancer recurrences were
observed in 12 patients and four patients died from meta-
stasis during the follow-up period. Most of the patients (97)
were post-menopausal (older than 50 years old). Tumours
varied in size at the time of diagnosis: subclinical tumours,
5%; TI, 15%; T2, 60%; T3, 15%; T4, 5%. Forty-eight per
cent (62) of the patients presented axillary lymph node
invasion and received adjuvant chemotherapy. Most of the
cancers analysed were invasive ductal carcinoma. However,
eight were infiltrating lobular and five were of the tubular
type.
A portion of each tumour was snap frozen in liquid nit-
rogen and stored at -70°C for immunohistochemistry and
flow cytometry, or fixed in buffered formalin for paraffin
embedding. Several biological parameters were analysed by
immunohistochemistry simultaneously with p53.
p53 antibodies
Four different commercially available monoclonal anti-p53
antibodies were used. Their characteristics are described in
Table I. PAb 1801 was used on 136 tumours, while the three
other antibodies were applied to 106 tumours.
Immunohistochemistry
The frozen sections were air dried for 10 min and fixed in
acetone at 18°C for 10 min. The paraffin sections were
pretreated three times by microwaving at 700 W in citrate
buffer pH 6.2 for 15 min. After standard inhibition of
endogenous peroxidase activity, staining of p53 protein was
performed with the different monoclonal antibodies under
the conditions detailed in Table I. Binding of the antibodies
was detected by using the ABC immunoperoxidase system
(Vectastain, Vector). All series included positive controls.
Negative controls included substitution of monoclonal
antibody by phosphate-buffered saline (PBS). All controls
gave satisfactory results. In addition to p53 antibodies,
immunohistochemistry was performed for most of the patients
(see Table III) on frozen sections using different antibodies
directed against oestrogen and progesterone receptors
(Abbott Kit, Rungis, France), EGF receptor (mouse mono-
clonal antibody EGFR1, Amersham, Les Ullis, France), Ki 67
(mouse monoclonal antibody, Dakopatts, Trappes, France).
Results were evaluated by a semiquantitative method
(Jacquemier et al., 1986). The p53 protein was revealed by a
nuclear staining, and quantitated in terms of percentage of
positive cells.
Flow cytometry
Tumour ploidy and S-phase were analysed by FACscan (Beck-
ton Dickinson) on frozen-thawed fragments stained with
propidium iodide. The coefficient of variation was below 5%
for all statistical analyses.
PCR-SSCP analysis
PCR conditions, pairs of primers used, and SSCP conditions
were as previously described (Mazars et al., 1992) except for
amplification of sequences in exon 4, which were as follows:
A, TGCACCAGCAGCTCCTACAC; B, CATGGAAGC-
CAGCCCCTCAG. The intensity ratios of mutated vs wild-
type bands were evaluated by densitometry scanning of the
autoradiograms. Autoradiograms were processed on a visage
system image analysis workstation (Millipore, Bedford, MA,
USA) and quantified.
Statistical analysis
Evaluation of the data was performed using an IBM-
compatible statistical analysis package program (Medlog
Logisoft). The probability of disease-free survival was cal-
culated for patients using the life table method and general-
ised salvage (Mantel-Cox) using the BMDP statistical
software. Chi-square tests were used to compare levels of p53
protein expression and several other prognostic factors:
tumour size, hormone receptor status, ploidy and lymph
node status.
Results
Immunohistochemistry assays ofp53 protein
We analysed 136 primary breast carcinomas for p53 staining
by immunohistochemistry. For this purpose we used four
commercially available antibodies, MAbs 1801, 240, D07
and DOI (Table I). In most positive cases, nuclear staining
was observed with all four monoclonal antibodies. However,
MAb 240 could occasionally give a cytoplasmic staining,
which we did not take into account in the absence of con-
comitant nuclear staining. The intensity of staining varied
from one tumour to another but was generally homogeneous
within a given sample. No positive staining could be
observed in normal mammary tissue. Only the percentage of
positive cells was taken into account for statistical analysis,
independently of the variation in intensity.
The numbers of positively staining tumours varied depend-
ing on the antibody used: MAbs 1801, 240, D07 and DOl
gave 20%, 24.5%, 20.1% and 29% positive tumours respec-
tively (Table I). Within a section, differences were also seen
in the proportions of p53-positive cells. These ranged from
29% with MAb 1801 to 51% with MAb DOI. Overall, 40
tumours (38%) presented positive immunostaining with at
least one antibody. Of these, 15 were positive with all four
antibodies, nine with a combination of three antibodies, six
with two antibodies and ten with only one.
Correspondence between p53 antibody staining and
PCR-SSCP analysis
These differences between antibodies in the numbers of
positive tumours and in the proportions of stained cells led
Table I Characteristics of the four monoclonal antibodies used, percentage of positive cells and positive cases for each antibody
Monoclonal Binding site Number Positive Mean percentage
antibody (amino acids) Source Condition of utilisation of cases cases of positive cellsa
MAb 1801 32-79 Oncogene Science Frozen sections, 136 n = 24 (17%) 29
Clinisciences, France 5gSgml', I h,
room temperature
MAb 240 156-355 Novocastra Frozen sections, 106 n = 21 (20%) 37
1:10 dilution, overnight/4°C
MAb D07 1-45 Novocastra Frozen sections, 106 n = 26 (24.5%) 45
TEBU, France 1:100 dilution, 1 h,
room temperature
MAb DOI 1-45 Immunotech, Paraffin sections, 106 n = 31 (29%) 51
Marseille, France 1:300 dilution, I h,
room temperature
after microwave
pretreatment
All combined 106 n=40 (38%)
aNot significant with chi-square test.848 J. JACQUEMIER et al.
us to test for the presence of a mutation at the DNA level.
This was performed using the PCR-SSCP method in a panel
of tumour sections presenting positive immunostaining. Sec-
tions to be analysed at the molecular level were selected
according to the number of cells stained with the aim of
setting up a panel of samples showing strong, medium and
low positivity (Table II). Stained tissue sections were scraped,
processed for DNA extraction and sequences within exons
4-9 of the p53 gene were amplified by PCR. Radiolabelled
PCR fragments were subsequently analysed by SSCP and
mutated DNA sequences identified because of their variant
electrophoretic patterns. Although the method would not
apply for exact quantification, we found that it could be
helpful to estimate the ratio of mutated versus wild-type p53
sequence in a given DNA sample. To verify this, we per-
formed a PCR-SSCP analysis on a cloned mutant p53
sequence serially diluted with a cloned wild-type sequence. As
shown in Figure 1, the relative intensities of the mutated and
wild-type bands were proportional to the input of their
templates. We then performed a PCR-SSCP analysis on 17
sections, of which nine were highly positive, three showed
medium to low staining and five low to negative staining
(Table II). It is noticeable, however, that most sections dis-
played different intensities of staining depending on the
antibody used (Figure 2). Only in a minority of sections did
we find similar staining intensities with all four antibodies.
Mutations were identified in 15 of 17 cases, and the relative
intensities of the shifted SSCP bands were evaluated as de-
a
C
DS
-
WT conformer -g
WT conformer -'
Mutated conformer
(codon 156)
Figure 1 Sensitivity ofp53 mutation detection by PCR-SSCP in
a dilution test. Wild-type and mutated p53 template DNAs
(CMVp53wt plasmid and CMVp53aal56 for the mutant) were
mixed with increasing dilution ratios as indicated on the top of
the figure and subsequently amplified in a radioactive PCR
experiment. Radiolabelled PCR fragment were subjected to SSCP
analysis and the mutated and wild-type single-stranded con-
formers characterised according to their migration patterns. DS
indicates the position of the double-stranded molecule.
scribed in Materials and methods, and compared with the
immunostaining results (Table II). Whereas a number of
tumours presented concordant results with immunohisto-
chemistry and SSCP, this was not generally the case. Sections
showing low levels of immunoreactivity could present highly
prevalent mutated bands on the SSCP gel (sample 5 in Table
b
T WT
T WT
Figure 2 Comparison of p53 immunohistochemical staining and the PCR-SSCP patterns. Each panel shows on the left side p53
tumour section staining and on the right the corresponding PCR-SSCP experiment performed on DNA extracted from a serial
section. a, Sample 6 stained with MAb DOI showing 40% positive cells; the mutated/wild-type sequences ratio was less then 25%.
b, Sample 5 stained with MAb D07 revealing 10% positive cells, whereas the mutated/wild-type ratio was higher than 75%. c,
Sample 8 stained with MAb DOI showing 5% positive cells and a ratio of 50-75%. d, Sample 2 stained with MAb D07 showing
80% positive cells, whereas the ratio was 50-75%. Mutated conformers are indicated by arrows; lane T corresponds to tumour
DNA and WT to a normal control DNA. Mutated/wild-type band intensity ratios were evaluated as described in Materials and
methods.p53 ANTIBODIES AND PCR-SSCP 849
Table II p53 expression in 17 cases of breast cancer detected by
immunohistochemistry and comparison with SSCP analysis
Sample SSCP analysis Immunohistochemistry analysisa
no. Exon Intensity MAb 1801 MAb DO] MAb D07 MAb 240
1 4 ++ 80 40 70 0
2 4 +++ 80 50 80 0
3 4 ++ 0 0 0 20
4 5 ++++ 80 20 80 20
5 5 ++++ 1 70 10 20
6 5 + 1 40 20 0
7 5' +++ 30 70 80 40
8 5' +++ 0 5 2 0
9 5' ++ 0 40 1 0
10 5' + 5 40 1 5
11 6 + + 80 80 80 80
12 6 + + 60 80 80 60
13 8 + 30 0 20 0
14 8 + + 30 80 80 80
15 8 + + 20 80 70 30
16 - - 40 60 60 60
17 - - 5 40 10 30
'Percentage of cells stained with the different antibodies. bRelative intensity of
the shifted bands. +, <25%; + +, <50%; + + +, <75%; + + + +, >75%.
Table III Correlation between the different prognostic criteria studied and the expression of
p53 protein expression with a minimum of one positive antibody
p53 expression
Number Percentage
Number ofpositive of positive
Criterion of cases cases cases X2 P
Tumour size
<20 mm
>20 mm
ND
Histological grade
I
II
III
ND
Lymphoid stromal
reaction
0
+
+ +
ND
Nodal status
N=0
N<4
N>4
ND
ER status
Negative
Positive
ND
PR status
Negative
Positive
ND
Ki 67
<15%
>15%
ND
EGFR
Negative
Positive
ND
Ploidy
Diploid
Aneuploid
ND
40
91
6
18
74
40
5
72
42
16
7
66
34
28
9
41
95
I
62
74
I
77
44
16
99
19
19
45
84
8
11
28
2
14
23
15
16
8
15
12
9
23
17
26
14
16
22
24
11
7
31
28
72
36
59
38.5
41
20.5
42
33
25
57.5
42.5
65
35
42
58
69
31
18
82
0.029 0.86
21.96 <0.0001
7.23
2.09
0.026
0.3
18.33 <0.0001
7.5 0.0061
9.78
7.11
0.0018
0.0076
6.5 0.037
ND, not determined; ER, oestrogen, receptor; PR, progesterone receptor; EGFR, epidermal
growth factor receptor.850 J. JACQUEMIER et al.
II) and, conversely, samples with highly positive staining
exhibited a mutated/wild-type band ratio of about 50:50
(samples 11 and 12, Table II). We conclude that the propor-
tions of p53-stained cells do not give an exact representation
of the number of cancer cells bearing a gene mutation within
a tumour.
Correlation with different biological parameters
Positive p53 reactivity was tested for correlations with com-
mon clinicopathological parameters and with recent prognos-
tic markers such as immunohistochemical measurement of
EGFR and Ki 67 levels, as well as ploidy (Table III).
Interestingly, p53 positivity seemed to be dependent on the
type of tumour tested, since only infiltrating ductal car-
cinomas stained positively, whereas tumours of other types
scored negative. Statistically significant correlations were
found with a number of parameters known to be associated
with poor prognosis (Table III). For instance, positive p53
reactivity was strongly correlated with grade III disease
(P = 0.0001), loss of oestrogen receptor (P = 0.0001) or pro-
gesterone receptor (P = 0.0061) expression, positive Ki 67
staining (P = 0.0018) and EGFR expression (P = 0.0076).
Less significant values were obtained with aneuploidy or
lymphoid stromal reaction. These results indicate that
positive p53 immunostaining is associated with highly pro-
liferative or aggressive breast carcinoma showing most of the
signs of aggressiveness. However, it is interesting to note that
no association could be found with axillary lymph node
involvement. These results were independent of the antibody
used.
p53 expression and clinical evolution ofthe disease
In order to assess the prognostic value of positive p53
immunostaining and compare it with that of usual markers
ofprognosis, we performed an univariate analysis (Table IV).
The results indicate that, in the presently studied set of
patients, the classical prognostic parameters were correlated
with disease-free survival such as tumour size (P= 0.043),
nodal status (P = 0.0030), oestrogen receptor (P= 0.0108)
and progesterone receptor (P = 0.011).
In contrast, histoprognostic grade and p53 staining were
not correlated with disease-free survival for this short period
of follow-up. This absence of correlation was observed
whatever the antibody used.
Discussion
Abnormal expression of p53 protein has been widely studied
in human breast cancer, and most investigators conclude an
association with aggressive forms of the disease (Iwaya et al.,
1991; Ostrowski et al., 1991; Isola et al., 1992; Thor et al.,
1992). However, important differences can be found from
one study to another, the number of positively stained sam-
ples ranging from 22% to more than 50%. In the present
study, we used a combination of four commercially available
monoclonal antibodies to assess the accumulation of p53
protein in a series of 136 primary breast cancers. We
observed 38% of the tumours staining positively with at least
one antiserum. Numbers were lower when each antibody was
considered individually, ranging from 17% to 30%. Our
Table IV Univariate analysis of actuarial disease-free survival
Number Disease-free survival (%)
Criterion of cases Two years Three years P
Tumour size
<20 mm 40 - -
>20 mm 91 87 79 0.043
ND 6
Histological grade
I 18 - -
II 74 91 81 0.45
III 40 85 85
ND 5
Nodal status
Negative 66 - - 0.003
Positive 62 84 730.3
ND 9
ER status
Negative 41 78 62 0.0108
Positive 95 94 91
ND 1
PR status
Negative 62 80 69
Positive 74 96 92 0.0112
ND 1
p53 statusa
Negative 66 90 87
Positive 40 85 64 0.17
ND 31
PAb 1801b
Positive 24 90 60 0.35
PAb 240b
Positive 21 87 87 0.75
DOlb
Positive 31 86 65 0.19
DO7b
Positive 26 92 69 0.54
ND
aGlobal status with four antibodies. "By comparison with the 66 cases negative
with four antibodies.p53 ANTIBODIES AND PCR-SSCP 851
numbers are in agreement with those reported by Thor et al.
(1992), but remain low compared with those reported by a
number of other investigators (Cattoretti et al., 1988; Bartek
et al., 1991; Horak et al., 1991). Variations might reflect
heterogeneity between the tested cohorts of tumours, as
testified by the larger numbers of p53-positive cases observed
in Li--Fraumeni patients compared with a population of
sporadic breast cancers (Thor et al., 1992), but technical
conditions could also account for these disparities. In fact,
the conditions of fixation (type of fixative and duration of
the process) and antibody used have been shown to influence
greatly the numbers of positive cases and the patterns of
staining, such as the numbers of stained cells and cytoplasmic
positivity (Bartek et al., 1990a, b). Some of our own observa-
tions (data not shown), as well as variations in the propor-
tions of tumour cells showing immunoreactivity when
different antibodies were compared - some tumours could
show 70 or 80% positive cells with a given MAb and be
negative or weakly positive with another antiserum - confirm
that p53 immunostaining depends greatly on the conditions
and reagents used in the test. Our data indicate that using
several antibodies in combination may reduce the extent of
the variations. Results by Varley et al. (1991) and Allred et
al. (1993) further support this observation.
These variations in staining patterns as well as reports on
possible discrepancies between immunohistochemistry and
analyses for mutations at the DNA level (Borresen et al.,
1991; Thompson et al., 1992) led us to perform a com-
parative search for mutations in the p53 gene using PCR-
SSCP on a selected set of p53-positive breast tumours. Our
data suggest that there is a good overlap between the
presence of a mutation at the DNA level and positive
immunostaining in breast cancer since only 2/17 samples
scored negative upon PCR-SSCP analysis. The correspon-
dence might even be better given the fact that mutations may
be missed by PCR-SSCP, as shown by some of our com-
parative tests with DGGE (C. Moyret, C. Theillet, L. Puig,
J.P. Moles, G. Thomas & R. Hamelin, submitted). Therefore,
the two tumours in which no mutation was detected despite
the presence of positive staining may still bear a mutated p53
allele. If, according to the present data, positive immuno-
staining often corresponds to the presence of a mutation at
the genetic level, the reverse is not always true. We used an
inverse approach by testing by immunohistochemistry
tumours which we had previously analysed for PCR-SSCP
and found that most mutants presented p53 staining; only
nonsense mutants were negative (J.P. Moles & C. Theillet,
unpublished results). The next question we asked was if the
number of cells stained with an anti-p53 antibody within a
tumour section reflected the number of cells actually bearing
a mutated p53 gene. As a matter of fact, a number of studies
have shown that some breast tumours could present focal
p53 staining corresponding to islets of p53-positive cells
(Bartek et al., 1991; Davidoff et al., 1991b; Horak et al.,
1991). These results, added to some of our SSCP observa-
tions showing that the wild-type allele was frequently
retained in tumours presenting mutated p53 sequences
(Mazars et al., 1992), suggested to us that the mutation
might be present only in a fraction of the cancer cells form-
ing these samples. Therefore, we wanted to verify if the
proportions of cancer cells stained by immunohistochemistry
were concordant with the signal ratio ofmutated to wild-type
sequences in the SSCP analyses, thus implying that p53
staining was indicative of the actual number ofmutated cells.
The results presented here indicate that while some concor-
dance could be found some disparities also existed. Hence,
we conclude that p53 staining is a somewhat imperfect re-
flection of the prevalence of p53 mutation and this is, in our
mind, further supported by differences in staining when
different antibodies are compared. Furthermore, hetero-
geneity in staining might be increased by physiological re-
sponses such as stabilisation of mild p53 in response to a
genotoxic stress.
Positive p53 immunostaining has, in a number of reports,
been correlated with factors associated with poor prognosis,
early relapse or shortened disease-free survival (Thor et al.,
1992; Allred et al., 1993). Only two studies did not show
similar correlations (Varley et al., 1991; Poller et al., 1992).
Most studies show a correlation in either monoparametric
(Iwaya et al., 1991; Ostrowski et al., 1991; Isola et al., 1992;
Thor et al., 1992) or multiparametric analysis. In our series
such a correlation could not be observed. This could be
attributed to a short follow-up. In contrast, most classical
parameters, such as nodal status or oestrogen and pro-
gesterone receptors, were significantly correlated. This
suggests that, in this series, p53 detected by immunohisto-
chemistry is not indicative of early recurrence.
Despite the fact that immunostaining does not permit the
detection of all mutations affecting p53 (nonsense mutations
do not lead to p53 accumulation), recent reports showing the
possibility of p53 staining in the absence of detectable muta-
tions are an additional argument in favour of this method in
the assessment of high-risk breast cancer patients. However,
the variations in staining patterns and numbers of positive
tumours one observed depending on the antibody and/or
technical conditions used necessitates standardisation of the
methods and reagents used in such studies.
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